- Home
- BLUE
BLUE
bluebird bio Inc.
as 11-21-2024 4:00pm EST
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SOMERVILLE |
| Market Cap: | 78.7M | IPO Year: | 2013 |
| Target Price: | $3.03 | AVG Volume (30 days): | 5.5M |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.29 - $5.53 | Next Earning Date: | 11-14-2024 |
| Revenue: | $53,120,000 | Revenue Growth: | 144.50% |
| Revenue Growth (this year): | 199.14% | Revenue Growth (next year): | 186.62% |
Stock Insider Trading Activity of bluebird bio Inc. (BLUE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Klima Thomas J | BLUE | See Remarks | Sep 30 '24 | Sell | $0.53 | 1,006 | $528.85 | 170,000 | |
| Obenshain Andrew | BLUE | President and CEO | Sep 30 '24 | Sell | $0.53 | 34,780 | $18,269.93 | 375,218 |
Latest bluebird bio Inc. News
BLUE Breaking Stock News: Dive into BLUE Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
bluebird bio Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Benzinga
6 days ago
JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options
GuruFocus.com
7 days ago
bluebird bio Inc (BLUE) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...
Zacks
8 days ago
Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
Associated Press Finance
8 days ago
Bluebird: Q3 Earnings Snapshot
Business Wire
8 days ago
bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance
Business Wire
15 days ago
bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call
Business Wire
17 days ago
bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Compare BLUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLUE bluebird bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.